A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Public ClinicalTrials.gov record NCT02421939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Study identification
- NCT ID
- NCT02421939
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Enrollment
- 371 participants
Conditions and interventions
Conditions
Interventions
- Azacitidine Drug
- FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin) Drug
- LoDAC (Low Dose Cytarabine) Drug
- MEC (Mitoxantrone, Etoposide, Cytarabine) Drug
- gilteritinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 19, 2015
- Primary completion
- Sep 16, 2018
- Completion
- Feb 24, 2025
- Last update posted
- Dec 3, 2025
2015 – 2025
United States locations
- U.S. sites
- 37
- U.S. states
- 23
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site US10011 | Birmingham | Alabama | 35294-0006 | — |
| Site US10012 | Los Angeles | California | 90095-1752 | — |
| Site US10076 | Orange | California | 92868 | — |
| Site US10073 | San Francisco | California | 94143 | — |
| Site US10067 | New Haven | Connecticut | 06504 | — |
| Site US10045 | Gainesville | Florida | 32610 | — |
| Site US10081 | Atlanta | Georgia | 30342 | — |
| Site US10006 | Chicago | Illinois | 60637 | — |
| Site US10075 | Westwood | Kansas | 66205 | — |
| Site US10074 | Louisville | Kentucky | 40202 | — |
| Site US10048 | New Orleans | Louisiana | 70112 | — |
| Site US10005 | Baltimore | Maryland | 21201 | — |
| Site US10034 | Boston | Massachusetts | 02114 | — |
| Site US10022 | Boston | Massachusetts | 02215 | — |
| Site US10085 | Boston | Massachusetts | 02215 | — |
| Site US10087 | Detroit | Michigan | 48201 | — |
| Site US10057 | Minneapolis | Minnesota | 55455 | — |
| Site US10023 | Lebanon | New Hampshire | 03756-1000 | — |
| Site US10027 | Hackensack | New Jersey | 07601 | — |
| Site US10077 | New Brunswick | New Jersey | 08903 | — |
| Site US10001 | Buffalo | New York | 14263 | — |
| Site US10037 | New York | New York | 10029 | — |
| Site US10008 | New York | New York | 10032 | — |
| Site US10013 | New York | New York | 10065 | — |
| Site US10072 | New York | New York | 10065 | — |
| Site US10046 | Syracuse | New York | 13210 | — |
| Site US10024 | Durham | North Carolina | 27710 | — |
| Site US10078 | Winston-Salem | North Carolina | 27157 | — |
| Site US10044 | Cleveland | Ohio | 44106 | — |
| Site US10084 | Columbus | Ohio | 43210 | — |
| Site US10058 | Oklahoma City | Oklahoma | 73104 | — |
| Site US10041 | Hershey | Pennsylvania | 17033 | — |
| Site US10010 | Philadelphia | Pennsylvania | 19104 | — |
| Site US10080 | Philadelphia | Pennsylvania | 19107 | — |
| Site US10014 | Charleston | South Carolina | 29425 | — |
| Site US10063 | Nashville | Tennessee | 37232-0656 | — |
| Site US10035 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02421939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2025 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02421939 live on ClinicalTrials.gov.